Skip to main content
Clinical Trials/NCT04633629
NCT04633629
Unknown
Not Applicable

Interest of Lung Ultrasound (LUS) in Therapeutic Adaptation of Patients Hospitalized in Medical Department for Acute Heart Failure (AHF).

University Hospital, Grenoble0 sites94 target enrollmentDecember 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Heart Failure
Sponsor
University Hospital, Grenoble
Enrollment
94
Primary Endpoint
Lung ultrasound aspect according to diuretics dosage evolution.
Last Updated
5 years ago

Overview

Brief Summary

Evaluate lung ultrasound aspect according to diuretics dosage evolution in patients hospitalized for acute heart failure.

Detailed Description

EPPICA is an observational and prospective cohort study. The study goal is to evaluate LUS aspect evolution according to diuretics dosage in patients hospitalized for acute heart failure.

Registry
clinicaltrials.gov
Start Date
December 2020
End Date
October 2021
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University Hospital, Grenoble
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Acute heart failure diagnosed by a senior physician in the medical department, with a confirmation of a second senior physician.
  • Hospitalised in the medical department.
  • No objection from the patient of his trusted person.

Exclusion Criteria

  • Administrative supervision or deprived of their liberty
  • Pulmonary conditions distracting lung ultrasound (pneumonectomy, pulmonary fibrosis)
  • Chronically dialysed

Outcomes

Primary Outcomes

Lung ultrasound aspect according to diuretics dosage evolution.

Time Frame: LUS will be performed daily during the whole hospitalisation length (on average 7 days).

B-lines number on LUS

Secondary Outcomes

  • Lung ultrasound aspect according to clinical signs of acute heart failure (crackling auscultation or lower limbs edema)(LUS and clinical examination will be performed daily during the whole hospitalisation length (on average 7 days).)
  • Lung ultrasound aspect according to early prognosis (re-hospitalisation or mortality within 30 days after discharge)(LUS will be performed daily during the whole hospitalisation length (on average 7 days). Patient will be called 30 days after discharge.)
  • Lung ultrasound aspect according to acute kidney injury (based on plasmatic creatinine levels).(LUS will be performed daily during the whole hospitalisation length (on average 7 days). Plasmatic creatinine measure will be performed at least weekly.)
  • Feasibility of daily LUS in medical department.(LUS will be performed daily during the whole hospitalisation length (on average 7 days).)
  • Interest of LUS compared to clinical examination at discharge.(LUS and clinical examination will be performed daily during the whole hospitalisation length (on average 7 days).)

Similar Trials